Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Phenotypic screening the host antimicrobial responses towards the eradication of Mycobacterium tubercuosis

Objective

The co-evolution between hosts and their parasites is one of the most fascinating examples of evolutionary adaptation. However, there is a paucity of information on how the human immune system co-adapts to the parasites phenotypic plasticity, and how it dynamically rearranges its molecular phenotypes aiming to counteract the pathogenic threats. Hence, many therapies for the treatment of intracellular bacteria-related infection (e.g. tuberculosis) are currently obsolete, especially because of the rise in drug resistance. In this framework, the main goal of my proposal is to decipher the unexplored phenotype ‘bar-codes’ of host-pathogen interaction, in order to reversely engineer a drug delivery platform aiming to target infected cells only, and to eradicate intracellular parasites. The final aim will be that of eradicating the severe intracellular pathogens Mycobacterium tuberculosis (Mtb), as it is the major cause of mortality related to bacterial infection worldwide. According to the World Health Organisation, in fact, approximately one-third of the world’s population is asymptomatically affected by TB, with about 9 million new cases of per year (of which 11% are children under 15 years), and 1.4 million of deaths. Despite decades of control programs, TB is still second only to HIV as the greatest killer worldwide due to a single infectious agent (the average killing rate of TB is 3 people per minute). This project will thus explore the molecular bases of Mtb-host interaction. These investigations will be used to engineer 'super-selective' polymeric nanoparticles targeting infected cells only (thus avoiding side effects), and to eradicate intracellular parasite. This will be done while adopting strategies that counteract the development drug resistance. Hence, this project will avoid falling in what has been called as the potential new ‘Dark Middle Age” era of lack of antibiotics.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MSCA-IF-EF-ST - Standard EF

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-MSCA-IF-2017

See all projects funded under this call

Coordinator

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 170 121,60
Address
CARRER BALDIRI REIXAC PLANTA 2A 10-12
08028 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 170 121,60
My booklet 0 0